Amarin (AMRN) to Release Quarterly Earnings on Wednesday

Amarin (NASDAQ:AMRN) is set to issue its quarterly earnings data before the market opens on Wednesday, May 1st. Analysts expect the company to announce earnings of ($0.04) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Amarin (NASDAQ:AMRN) last announced its quarterly earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.04. Amarin had a negative net margin of 19.26% and a negative return on equity of 10.47%. The business had revenue of $74.71 million during the quarter, compared to analysts’ expectations of $72.46 million. On average, analysts expect Amarin to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Amarin Trading Up 2.0 %

AMRN stock opened at $0.88 on Wednesday. The stock has a market capitalization of $362.74 million, a price-to-earnings ratio of -6.31 and a beta of 1.98. The firm’s 50-day moving average price is $0.99 and its two-hundred day moving average price is $0.93. Amarin has a 12-month low of $0.65 and a 12-month high of $1.49.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Amarin in a research report on Friday, January 12th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat, Amarin has an average rating of “Hold” and a consensus price target of $1.08.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.